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Abstract
Murine double minute-2 (MDM2) is an intracellular molecule with multiple biologic functions. It serves as a negative
regulator of p53 and thereby limits cell cycle arrest and apoptosis. Because MDM2 blockade suppresses tumor cell
growth in vitro and in vivo, respective MDM2 inhibition is currently evaluated as anti-cancer therapy in clinical trials.
However, the anti-proliferative effects of MDM2 inhibition also impair regenerative cell growth upon tissue injury.
This was so far documented for tubular repair upon postischemic acute kidney injury and might apply to wound heal-
ing responses in general. Furthermore, MDM2 has numerous p53-independent effects. As a new entry, MDM2 was
identified to act as a co-transcription factor for nuclear factor–kappa-light-enhancer of activated B cells (NF-κB) at
cytokine promoters. This explains the potent anti-inflammatory effects of MDM2 inhibitors in vitro and in vivo. For
example, the NF-κB–antagonistic and p53-agonistic activities of MDM2 inhibitors elicit potent therapeutic effects on
experimental lymphoproliferative autoimmune disorders such as systemic lupus erythematosus. In this review, we dis-
cuss the classic p53-dependent, the recently discovered p53-independent, and the NF-κB–agonistic biologic functions
of MDM2. We describe its complex regulatory role on p53 and NF-κB signaling and name areas of research that may
help to foresee previously unexpected effects or potential alternative indications of therapeutic MDM2 blockade.
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Introduction
Murine double minute-2 (MDM2) is an intracellular protein with
oncoprotein functions, which is considered to be a valuable target
for cancer therapy for a variety of reasons: 1) MDM2 is an E3 ubiqui-
tin ligase that negatively regulates p53 mainly by ubiquitin-mediated
degradation, as such MDM2 suppresses coordinated cell cycle arrest
or apoptosis and promotes cell survival and growth [1]; 2) cell-type–
specific deletion of MDM2 recovers p53 and induces cell-type–specific
cell death [2]; 3)MDM2 is strongly expressed inmanymalignancies with
wild-type p53 as an alternate mechanism to disrupt the p53 pathway in
early cancer development [3,4]; 4) MDM2 overexpression is linked to
gain-of-function mutations in many tumors [1]; and 5) MDM2 block-
ade with suitable antagonists was shown to block tumor growth in a
number of models [5]. As such, a clinical trial is currently ongoing to
study the effects of the MDM2 antagonist RO5503781, in advanced
malignancies other than leukemia (www.clinicaltrials.gov).
There is a huge body of data that describes the p53-MDM2 reg-
ulatory feedback loop in various tumor cells, implicating that the sci-
entific rationale of qualifying MDM2 as a valuable therapeutic target
is based on tumor cell cycle control [5]. However, MDM2 has a
number of p53-independent effects [6] and tumor growth also depends
on tumor vasculature, tumor stroma, and an immunosuppressive tumor
environment, factors that have not yet been rigorously explored in the con-
text of MDM2. In this context, the recently discovered role of MDM2
in nuclear factor–kappa-light-enhancer of activated B cells (NF-κB) sig-
naling should be of enigmatic importance because it identifies MDM2
as the missing link between inflammation and carcinogenesis [7]. In
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this review, we focus on the expanding role of MDM2 as a regulator
of NF-κB signaling, innate immunity, and tissue inflammation and its
potential impact on tumor cell biology, cancer therapy, other abnormal
hyperproliferative syndromes, as well as wound healing.
The Classic p53-Dependent Role of MDM2 on
Cell Cycle Control
MDM2 is an oncoprotein based on its function as negative regulator
of tumor suppressor protein p53, which is one of the central regula-
tors of cell cycle. p53 has a pivotal role in stress response signaling
and its activation results in quiescence, senescence, or death of cells
with DNA damage, therefore avoiding aberrant mitosis and carcino-
genesis. MDM2 inhibits p53 transcriptional activity, it acts as E3
ubiquitin ligase ubiquitinating and targeting p53 for proteasomal
degradation, and it promotes the nuclear export of p53 (Figure 1).
Vice versa, MDM2 is a p53 target gene illustrating how MDM2 and
p53 form a tightly regulated negative feedback loop in which activated
p53 upregulates MDM2 expression, which in turn will target p53 for
degradation [3,8,9]. MDM2 deficiency leads to p53-driven, uncon-
trolled cell death already during embryonic development. This pheno-
type can be entirely rescued by concomitant deletion of p53 [10]. This
shows the absolute necessity of tight regulation of p53 by MDM2 in
normal tissues, as p53 overexpression results in dramatic apoptosis in
multiple organs [11]. However, MDM2 gene duplication or hyper-
activation eliminates p53-mediated growth control of cells with signif-
icant DNA damage that supports tumorigenesis. This MDM2 effect is
most prominent together with concomitant dysfunctional p53, which
applies to more than 50% of human cancers [4,9].
With genotoxic or cytotoxic stress, frequently preceding cell trans-
formation, p53 and MDM2 are activated by phosphorylation and
acetylation on specific residues, which results in their dissociation,
p53 stabilization, and consequent transcriptional up-regulation of p53
target genes leading to cell cycle arrest and DNA repair or to pro-
grammed cell death [12]. There are other crucial players regulating
the MDM2-p53 dynamic equilibrium, which form a very complex
network. For example, upon oncogenic stress, tumor suppressor ARF
is activated and binds to central domain of MDM2 to inhibit MDM2-
mediated ubiquitination and degradation of p53 [13]. Similarly, ribo-
somal stress induces several ribosomal proteins that interact with the
same region on MDM2 and, therefore, stabilize p53 [14]. The multi-
faceted MDM2-p53 relationship can be further exemplified by studies
suggesting opposite function of MDM2, not as a p53 inhibitor but as
a p53 enhancer. MDM2 stimulates p53 mRNA translation by binding
the p53mRNA, andmoreover, this interaction also suppressesMDM2’s
capacity to promote p53 ubiquitination and degradation [15].
p53-Independent Roles of MDM2 in Carcinogenesis
There is growing evidence that MDM2 has a number of p53-
independent functions in cell cycle regulation, differentiation, transcrip-
tion, or DNA synthesis [6,8]. Many of these p53-independent MDM2
roles foster cell transformation and tumorigenesis. A number of tumors
overexpress MDM2, which overcomes the pro-apoptotic effect of wild-
type p53 and fuels tumor growth [4,9]. Alternatively, amplified
MDM2 is coupled with non-functional and mutated p53 [4,9]. This
suggests that upregulated MDM2 on its own has additional growth
advantages independent of p53. For example, estrogen-induced breast
cancer cell proliferation requires a p53-independent MDM2-mediated
pathway to activate cell proliferation and p53 is not the key target of
MDM2 [16]. MDM2 also interacts with Rb, MTBP, Smads, and other
molecules which play a key role in cell cycle regulation and seem to con-
tribute to MDM2’s oncogenic effects independently of p53 [6,8]. p53
is also not required for MDM2 to promote the translation of the anti-
apoptotic protein XIAP, which accumulates in cancer cells and sup-
ports their resistance to radiation therapy [17]. Furthermore, blocking
MDM2 by small-molecule antagonists is known to inhibit MDM2
interactions with p73 [18] and E2F1 [19], resulting in enhanced p53-
deficient tumor cell apoptosis, or with HIF1a [20], inhibiting thus
tumor promotion and angiogenesis in p53-independent manner.
Interestingly, MDM2 can also display tumor suppression properties.
MDM2/p53 double-deficient mice had shorter tumor latency com-
pared to p53-null mice with MDM2 expression retained [21]. Further-
more, p53 is also not involved when MDM2 negatively regulates
insulin-like growth factor-1 receptor (IGF-1R) that protects cells from
DNA damage–induced apoptosis, thus allowing transformed cells to
undergo apoptosis [22,23]. MDM2 overexpression is also linked to in-
creased motility, invasive growth, and metastasis of cancer cells through
mechanism independent of its function in protein ubiquitination.
MDM2 promotes cancer cell mobility through protein-protein inter-
action with non-metastatic cells 2 protein (NME2). MDM2 over-
expression suppresses NME2-mediated inhibition of cell motility [24].
Together, p53-dependent and p53-independent effects of MDM2
mostly promote the proliferation of cells with DNA damage, tumor
growth, and metastasis.
The p53-Independent Role of MDM2 in
NF-κB Signaling
A novel and unexpected biologic function of MDM2 is its NF-κB–
agonistic effect during sterile tissue inflammation. Sterile inflammation
is a major element of non-infectious tissue injury, e.g., upon exposure
to toxins or ischemia-reperfusion. For example, postischemic acute
kidney injury involves a sterile inflammatory response that was dramat-
ically suppressed by MDM2 blockade with nutlin-3a [25]. This effect
was independent of p53, as it also occurred in p53-deficient mice,
whereas the anti-proliferative effect of MDM2 blockade on epithelial
healing was abrogated in p53-deficient mice. MDM2 blockade sup-
pressed the postischemic induction of pro-inflammatory cytokines
and chemokines, as well as the subsequent recruitment of leukocytes
to the site of injury. The mechanism underlying MDM2-mediated
inflammation was identified in vitro by showing that MDM2 acts as a
co-factor for NF-κB binding to its target gene promotor binding sites,
while upstream the outside-in signaling of NF-κB activation was inde-
pendent of MDM2 [25]. This was evidenced by electromobility shift
assay using lipopolysaccharide (LPS)-stimulated p53-deficient and
MDM2/p53 double-deficient mouse embryonic fibroblasts [25]. This
observation is consistent with a previous report showing that MDM2
blockade with nutlin suppresses LPS-induced lung inflammation and
that nutlin-3a impairs NF-κB DNA binding in neutrophils; however,
this effect of nutlin was dependent on the presence of p53 [26]. One
may speculate that this p53-independent biologic effect of MDM2
contributes to prolonged recovery of critically ill patients with MDM2
up-regulation [27]. Furthermore, MDM2 is overexpressed in human
atherosclerosis and MDM2 inhibition with nutlin-3–suppressed NF-κB–
dependent inflammation in vascular smooth muscle cells [28,29].
Complex Regulation among MDM2, NF-κB, and p53
It is an evolving paradigm that MDM2 links NF-κB and p53 signaling
by promoting NF-κB and blocking p53. NF-κB and p53 signaling are
1098 MDM2 and NF-κB Signaling Thomasova et al. Neoplasia Vol. 14, No. 12, 2012
both important genotoxic and cytotoxic stress response pathways that
are both deregulated in cancer [30]. Tissue injury activates NF-κB not
only to induce host defense but also to block apoptosis and to stimulate
regenerative cell growth. However, these effects become problematic in
the context of cancer. The majority of malignancies are associated with
long-term activation of NF-κB [31,32]. In contrast, the tumor sup-
pressor p53 is commonly inactivated in the tumor environment, which
further impairs cancer cell growth arrest and apoptosis. The opposite
functional effects of these two pathways on cell cycle control imply that
they need to be tightly co-regulated and kept in balance (Figure 1). In
fact, cross talk and reciprocal negative regulation of NF-κB and p53
signaling occurs at multiple levels [30].
Figure 1. Regulatory effects of MDM2 on NF-κB and p53 signaling pathways. MDM2 negatively regulates p53 in at least three different
ways, i.e., 1) MDM2 functions as the E3 ubiquitin ligase promoting ubiquitin-dependent proteasomal degradation of p53; 2) MDM2
facilitates nuclear export of p53 into the cell cytoplasm, moving p53 away from its site of action; 3) MDM2 directly interacts with
the p53 transcription activation domain, thus inhibiting p53 transcriptional activity; and 4) MDM2 activates the NF-κB signaling pathway
by enhancing the transcription of NF-κB/p65 but also acts as a non-redundant co-transcription factor for NF-κB target genes.
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NF-κB Suppresses p53 Signaling by Inducing MDM2
MDM2 is a target gene of NF-κB signaling; hence, NF-κB nega-
tively regulates p53 through up-regulation of MDM2 [30]. This effect
may involve the NF-κB target protein Bcl3 [33] as well as inhibitor of
nuclear factor kappa-B kinase subunit beta (IKK2) [34]. In addition,
NF-κB induces MDM2 to stimulate T cell activation and proliferation,
which in turn inhibits the p53 family tumor suppressor protein p73, in-
dependent of p53 [35].
p53 Regulates NF-κB Signaling
p53 negatively regulates NF-κB signaling [30]. For example, p53
competes with NF-κB for limited transcription co-factors such as
p300/CBP [36] or suppresses NF-κB transcriptional activity through
inhibition of IKKs and histone H3 kinase [37,38]. Obviously, p53-
mediated repression of NF-κB occurs rather at the level of protein-
protein interactions or protein modifications.
MDM2 Regulates NF-κB Signaling
As described above in detail, MDM2 acts as a co-factor for NF-κB
at target gene promoters, a process that is independent of p53 [25].
Furthermore, MDM2 directly induces the transcription of p65 by
interacting with Sp-1 binding sites in the p65 gene promoter of leu-
kemia cells, independent of their p53 status [39]. Moreover, MDM2
can upregulate expression of p100/NF-κB2 in lung cells. MDM2
sustains this function also when its p53-interaction domain is blocked
by nultin-3 or in p53-deficient lung cancer cells [40]. It is of note that
MDM2 can display different regulatory activities dependent on the
activation status of NF-κB in transformed cells with inactive p53.
In cells with normal levels of NF-κB activity, MDM2 induced NF-κB
overactivation and cell proliferation. In contrast, in cells that consti-
tutively overexpress NF-κB, MDM2 suppressed NF-κB signaling
and enhanced apoptosis [41].
Together, MDM2 is a regulator of p53 as well as of NF-κB sig-
naling and can tilt the balance of both pathways in both directions.
Depending on the context, MDM2 can act either pro-inflammatory
and pro-mitogenic or anti-inflammatory and pro-apoptotic.
Clinical Implications of Therapeutic
MDM2 Inhibition
The recently discovered additional functions of MDM2 may have
certain implications on the clinical use of MDM2 antagonists. These
can be divided into effects on tumor cells, on tumor stroma, on poten-
tial cancer therapy complications, and on alternative indications of
therapeutic MDM2 inhibition.
MDM2 Inhibition in Tumor Cells
The rationale to develop MDM2 inhibitors is based on the well
known p53-dependent mitogenic effects of MDM2 on tumor cells.
NF-κB signaling also promotes the survival and proliferation of non-
immune cells; hence, MDM2 inhibition that blocks NF-κB signaling
rather enhances tumor cell death, but this may depend on the tumor
cell NF-κB activation status [41]. The broad literature that documents
the beneficial effects of MDM2 blockade on tumor cell growth raised
the enthusiasm about MDM2 inhibition as a novel cancer therapy.
MDM2 Inhibition and Tumor Stroma
A significant part of the mass of solid tumors is stroma, consisting
of tumor vasculature, interstitial mesenchymal tissue, and immune
cell infiltrates that create an environment with its own dynamics.
Therapies that are designed to target tumor cells may have their own
effects on tumor stroma. While anti-proliferative therapies usually act
on tumor as well as on stroma cells, anti-inflammatory drugs might also
interact with the tumor stroma in a more specific way. The NF-κB–
antagonistic effects ofMDM2 inhibition should have anti-inflammatory
effects on those immune elements that are directed against tumor cells.
This way, MDM2 blockade might impair anti-tumor T and B cell
responses that help to control tumor mass and enhance the immuno-
suppressive environment generated by tumor-associated macrophages
and regulatory T cells. Even though, MDM2 blockade has proven
effective in many in vivo cancer animal models, it is reasonable to believe
that the immunosuppressive action of MDM2 inhibitors may limit the
efficacy of tumor control in certain malignancies.
Potential Side Effects of Therapeutic MDM2 Inhibition
The p53-agonistic activity of MDM2 inhibitors impairs regenerative
cell growth upon acute kidney injury [25]. Therefore, it is reasonable to
believe that this observation applies to other forms of wound healing, e.g.,
in the surgery setting. One should be reminded that the therapeutic pro-
file ofMDM2 inhibitors as anti-proliferative and anti-inflammatory drugs
is comparable to that of mammalian target of rapamycin (mTOR) inhib-
itors. mTOR inhibitors have a proven negative effect on wound healing,
which has affected its clinical use, e.g., during the early phase after solid
organ transplantation [42]. It will be important to explore during clinical
trials whether the use of MDM2 inhibitors is associated with a similar
effect on wound healing. Impaired wound healingmay affect the outcome
of episodes of acute renal failure that commonly occur in patients with
cancer after surgery or during treatment with several chemotherapeutics.
The same could apply to ischemic limb injury, myocardial infarction,
stroke, and chronic ulcers including ulcers of the gastrointestinal tract.
Furthermore, the anti-inflammatory effect of MDM2 inhibition may
suppress host defense and promote infectious complications.
Potential Other Indications of Therapeutic MDM2 Inhibition
The anti-inflammatory and anti-proliferative potential of MDM2
inhibition can elicit additive effects in other disease settings, especially
in autoimmune diseases. For example, systemic lupus erythematosus is
a polyclonal lymphoproliferative disorder characterized by expansion of
autoreactive T and B cell clones that cause systemic autoimmunity and
tissue inflammation. MDM2 inhibition with nutlin-3a dramatically
reduces both aspects of the disease by abrogating the abnormal prolif-
eration of lymphocytes and autoantibody production as well as the
immunopathology in multiple solid organs [43]. It is noteworthy that
MDM2 blockade with nutlin-3a had no effect on hematopoiesis and
did not cause neutropenia like it occurs with immunosuppressants
such as cyclophosphamide or mycophenolate mofetil, which are cur-
rently used for lupus therapy [43]. It remains to be studied whether
MDM2 inhibition can have similar advantageous effects on other
autoimmune disorders.
Summary and Perspective
MDM2 is a regulator of p53 as well as NF-κB signaling. MDM2
degrades p53 through its E3 ubiquitin ligase activity, but MDM2
also acts as a non-redundant co-transcription factor for NF-κB target
genes. This way, MDM2 has additive p53-dependent and NF-κB–
dependent (p53-independent) effects on the survival and growth of
malignant cells. For the future, it will be important to define the role
of MDM2-mediated NF-κB signaling in tumor stroma, tumor vas-
culature, and metastasis. Furthermore, establishing MDM2 inhibition
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as a novel cancer therapy will require a careful assessment of its poten-
tial suppressive effects on wound healing, tissue repair upon toxic or
ischemic injury, as well as host defense, three important and promising
areas to work on—experimentally and clinically—in the future. Finally,
the NF-κB–antagonistic and p53-agonistic effects of MDM2 inhibitors
represent a very promising drug activity profile to suppress lympho-
proliferative autoimmune disorders such as systemic lupus erythema-
tosus. Its potential to control lupus or other autoimmune disorders
needs to be further evaluated, in both preclinical as well as clinical settings.
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